Skip to content

Sándor Nardai

3 papers in the library · 100 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

ABSTRACT NUMBER: ESOC2026YS125 DIMETHYLTRYPTAMINE INHIBITS SPREADING DEPOLARISATION IN BRAIN SLICES OF SIGMA-1 RECEPTORKNOCKOUT MICE

European Stroke Journal May 1, 2026 Anna Zsigmond, Rita Frank, Botond Eröss et al.

Abstract Background and aims Spreading depolarizations (SDs) exacerbate neuronal injury during acute ischemic stroke (AIS). The sigma-1 receptor (S1R) agonist dimethyltryptamine (DMT) reduces cellular damage, inhibits SDs, and enhances neuronal survival in rodent models of AIS. Although DMT primarily acts on S1R, it also binds to aminergic receptors. Therefore, we aimed to determine the...

N,N-dimethyltryptamine mitigates experimental stroke by stabilizing the blood-brain barrier and reducing neuroinflammation.

Science Advances August 15, 2025 Marcell J László, Judit P Vigh, Anna E Kocsis et al. 9 citations

N,N-dimethyltryptamine (DMT) is a psychoactive molecule present in the human brain. DMT is under clinical evaluation as a neuroprotective agent in poststroke recovery. Yet, its mechanism of action remains poorly understood. In a rat transient middle cerebral artery occlusion stroke model, we previously showed that DMT reduces infarct volume. Here, we demonstrate that this effect is accompanied...

N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats

Experimental Neurology February 14, 2020 Sándor Nardai, Marcell J László, Attila Szabo et al. 91 citations

Background and purposeN,N-dimethyltryptamine (DMT) is an endogenous ligand of the Sigma 1 receptor (Sig-1R) with documented in vitro cytoprotective properties against hypoxia. Our aim was to demonstrate the in vivo neuroprotective effect of DMT following ischemia-reperfusion injury in the rat brain.MethodsTransient middle cerebral occlusion (MCAO) was induced for 60 min in male Wistar rats...